2018
DOI: 10.1097/01.ogx.0000532155.55081.57
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: BACKGROUND Treatment of newly diagnosed advanced-stage ovarian cancer typically involves cytoreductive surgery and systemic chemotherapy. We conducted a trial to investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery would improve outcomes among patients who were receiving neoadjuvant chemotherapy for stage III epithelial ovarian cancer. METHODS In a multicenter, open-label, phase 3 trial, we randomly assigned 245 patients who had at least stable… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

9
315
4
7

Year Published

2018
2018
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 176 publications
(335 citation statements)
references
References 3 publications
(3 reference statements)
9
315
4
7
Order By: Relevance
“…A recent randomized trial of HIPEC in ovarian cancer was published in the New England Journal of Medicine, demonstrating a remarkable 13-month advantage in median overall survival for those patients receiving a 90-min HIPEC with cisplatin after cytoreduction compared with cytoreduction alone. 22 Although these results are consistent with those reported for gastrointestinal tumors and support the role of HIPEC for peritoneal metastases in general, it is also important to appreciate that the management of peritoneal metastases goes beyond HIPEC. It is incumbent on peritoneal surgeons to develop better treatments focused on the peritoneal cavity.…”
supporting
confidence: 81%
“…A recent randomized trial of HIPEC in ovarian cancer was published in the New England Journal of Medicine, demonstrating a remarkable 13-month advantage in median overall survival for those patients receiving a 90-min HIPEC with cisplatin after cytoreduction compared with cytoreduction alone. 22 Although these results are consistent with those reported for gastrointestinal tumors and support the role of HIPEC for peritoneal metastases in general, it is also important to appreciate that the management of peritoneal metastases goes beyond HIPEC. It is incumbent on peritoneal surgeons to develop better treatments focused on the peritoneal cavity.…”
supporting
confidence: 81%
“…A recently published multicentre open-label phase III trial (OVHIPEC)219 randomised patients with stage III EOC with abdominal disease too extensive for UDS or after UDS with residual disease >1 cm, and after response to 3 cycles of NACT, to undergo IDS with or without HIPEC (cisplatin 100 mg/m 2 ). The addition of HIPEC to IDS resulted in a significantly longer PFS and OS without increasing toxicity.…”
Section: Resultsmentioning
confidence: 99%
“…Sodium thiosulfate has also been used to prevent cisplatin nephrotoxicity,31 32 but a possible drawback of its use is that it might reduce its desired anti-tumor effect 33. Nevertheless, sodium thiosulfate has been successfully used in a recent phase III trial in which no cases of renal toxicity were reported 4. Likewise, alpha-lipoic acid has also been shown to ameliorate cisplatin-induced acute kidney injury 34.…”
Section: Discussionmentioning
confidence: 99%
“…In other rare peritoneal diseases such as peritoneal pseudomyxoma and mesothelioma this strategy has already shown a survival benefit 2 3. Regarding frontline treatment of ovarian cancer, there has been limited data until the recent publication of a multicenter randomized phase III trial, showing a survival advantage in patients undergoing interval cytoreductive surgery with cisplatin-based hyperthermic intra-peritoneal chemotherapy 4. In recurrent ovarian cancer, cytoreductive surgery plus hyperthermic intra-peritoneal chemotherapy has also demonstrated a survival improvement over cytoreductive surgery alone 5…”
Section: Introductionmentioning
confidence: 99%